Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation

Di Cai, David S. Shames, Maria Gabriela Raso, Yang Xie, Young H. Kim, Jonathan R. Pollack, Luc Girard, James P. Sullivan, Boning Gao, Michael Peyton, Meera Nanjundan, Lauren Byers, John Heymach, Gordon Mills, Adi F. Gazdar, Ignacio Wistuba, Thomas Kodadek, John D. Minna

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Steroid receptor coactivator-3 (SRC-3) is a histone acetyltransferase and nuclear hormone receptor co-activator, located on 20q12, which is amplified in several epithelial cancers and well studied in breast cancer. However, its possible role in lung cancer pathogenesis is unknown. We found SRC-3 to be overexpressed in 27% of non-small cell lung cancer (NSCLC) patients (n = 311) by immunohistochemistry, which correlated with poor disease-free (P = 0.0015) and overall (P = 0.0008) survival. Twenty-seven percent of NSCLCs exhibited SRC-3 gene amplification, and we found that lung cancer cell lines expressed higher levels of SRC-3 than did immortalized human bronchial epithelial cells (HBEC), which in turn expressed higher levels of SRC-3 than did cultured primary human HBECs. Small interfering RNA-mediated downregulation of SRC-3 in high-expressing, but not in low-expressing, lung cancer cells significantly inhibited tumor cell growth and induced apoptosis. Finally, we found that SRC-3 expression is inversely correlated with gefitinib sensitivity and that SRC-3 knockdown results in epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancers becoming more sensitive to gefitinib. Taken together, these data suggest that SRC-3 may be an important oncogene and therapeutic target for lung cancer.

Original languageEnglish (US)
Pages (from-to)6477-6485
Number of pages9
JournalCancer Research
Volume70
Issue number16
DOIs
StatePublished - Aug 15 2010
Externally publishedYes

Fingerprint

Nuclear Receptor Coactivator 3
Lung Neoplasms
Cell Survival
Cell Proliferation
Neoplasms
Histone Acetyltransferases
Gene Amplification
Cytoplasmic and Nuclear Receptors
Oncogenes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Small Interfering RNA
Down-Regulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. / Cai, Di; Shames, David S.; Raso, Maria Gabriela; Xie, Yang; Kim, Young H.; Pollack, Jonathan R.; Girard, Luc; Sullivan, James P.; Gao, Boning; Peyton, Michael; Nanjundan, Meera; Byers, Lauren; Heymach, John; Mills, Gordon; Gazdar, Adi F.; Wistuba, Ignacio; Kodadek, Thomas; Minna, John D.

In: Cancer Research, Vol. 70, No. 16, 15.08.2010, p. 6477-6485.

Research output: Contribution to journalArticle

Cai, D, Shames, DS, Raso, MG, Xie, Y, Kim, YH, Pollack, JR, Girard, L, Sullivan, JP, Gao, B, Peyton, M, Nanjundan, M, Byers, L, Heymach, J, Mills, G, Gazdar, AF, Wistuba, I, Kodadek, T & Minna, JD 2010, 'Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation', Cancer Research, vol. 70, no. 16, pp. 6477-6485. https://doi.org/10.1158/0008-5472.CAN-10-0005
Cai, Di ; Shames, David S. ; Raso, Maria Gabriela ; Xie, Yang ; Kim, Young H. ; Pollack, Jonathan R. ; Girard, Luc ; Sullivan, James P. ; Gao, Boning ; Peyton, Michael ; Nanjundan, Meera ; Byers, Lauren ; Heymach, John ; Mills, Gordon ; Gazdar, Adi F. ; Wistuba, Ignacio ; Kodadek, Thomas ; Minna, John D. / Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. In: Cancer Research. 2010 ; Vol. 70, No. 16. pp. 6477-6485.
@article{2c3463cf5c704009aaab2a3f41429266,
title = "Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation",
abstract = "Steroid receptor coactivator-3 (SRC-3) is a histone acetyltransferase and nuclear hormone receptor co-activator, located on 20q12, which is amplified in several epithelial cancers and well studied in breast cancer. However, its possible role in lung cancer pathogenesis is unknown. We found SRC-3 to be overexpressed in 27{\%} of non-small cell lung cancer (NSCLC) patients (n = 311) by immunohistochemistry, which correlated with poor disease-free (P = 0.0015) and overall (P = 0.0008) survival. Twenty-seven percent of NSCLCs exhibited SRC-3 gene amplification, and we found that lung cancer cell lines expressed higher levels of SRC-3 than did immortalized human bronchial epithelial cells (HBEC), which in turn expressed higher levels of SRC-3 than did cultured primary human HBECs. Small interfering RNA-mediated downregulation of SRC-3 in high-expressing, but not in low-expressing, lung cancer cells significantly inhibited tumor cell growth and induced apoptosis. Finally, we found that SRC-3 expression is inversely correlated with gefitinib sensitivity and that SRC-3 knockdown results in epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancers becoming more sensitive to gefitinib. Taken together, these data suggest that SRC-3 may be an important oncogene and therapeutic target for lung cancer.",
author = "Di Cai and Shames, {David S.} and Raso, {Maria Gabriela} and Yang Xie and Kim, {Young H.} and Pollack, {Jonathan R.} and Luc Girard and Sullivan, {James P.} and Boning Gao and Michael Peyton and Meera Nanjundan and Lauren Byers and John Heymach and Gordon Mills and Gazdar, {Adi F.} and Ignacio Wistuba and Thomas Kodadek and Minna, {John D.}",
year = "2010",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-10-0005",
language = "English (US)",
volume = "70",
pages = "6477--6485",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation

AU - Cai, Di

AU - Shames, David S.

AU - Raso, Maria Gabriela

AU - Xie, Yang

AU - Kim, Young H.

AU - Pollack, Jonathan R.

AU - Girard, Luc

AU - Sullivan, James P.

AU - Gao, Boning

AU - Peyton, Michael

AU - Nanjundan, Meera

AU - Byers, Lauren

AU - Heymach, John

AU - Mills, Gordon

AU - Gazdar, Adi F.

AU - Wistuba, Ignacio

AU - Kodadek, Thomas

AU - Minna, John D.

PY - 2010/8/15

Y1 - 2010/8/15

N2 - Steroid receptor coactivator-3 (SRC-3) is a histone acetyltransferase and nuclear hormone receptor co-activator, located on 20q12, which is amplified in several epithelial cancers and well studied in breast cancer. However, its possible role in lung cancer pathogenesis is unknown. We found SRC-3 to be overexpressed in 27% of non-small cell lung cancer (NSCLC) patients (n = 311) by immunohistochemistry, which correlated with poor disease-free (P = 0.0015) and overall (P = 0.0008) survival. Twenty-seven percent of NSCLCs exhibited SRC-3 gene amplification, and we found that lung cancer cell lines expressed higher levels of SRC-3 than did immortalized human bronchial epithelial cells (HBEC), which in turn expressed higher levels of SRC-3 than did cultured primary human HBECs. Small interfering RNA-mediated downregulation of SRC-3 in high-expressing, but not in low-expressing, lung cancer cells significantly inhibited tumor cell growth and induced apoptosis. Finally, we found that SRC-3 expression is inversely correlated with gefitinib sensitivity and that SRC-3 knockdown results in epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancers becoming more sensitive to gefitinib. Taken together, these data suggest that SRC-3 may be an important oncogene and therapeutic target for lung cancer.

AB - Steroid receptor coactivator-3 (SRC-3) is a histone acetyltransferase and nuclear hormone receptor co-activator, located on 20q12, which is amplified in several epithelial cancers and well studied in breast cancer. However, its possible role in lung cancer pathogenesis is unknown. We found SRC-3 to be overexpressed in 27% of non-small cell lung cancer (NSCLC) patients (n = 311) by immunohistochemistry, which correlated with poor disease-free (P = 0.0015) and overall (P = 0.0008) survival. Twenty-seven percent of NSCLCs exhibited SRC-3 gene amplification, and we found that lung cancer cell lines expressed higher levels of SRC-3 than did immortalized human bronchial epithelial cells (HBEC), which in turn expressed higher levels of SRC-3 than did cultured primary human HBECs. Small interfering RNA-mediated downregulation of SRC-3 in high-expressing, but not in low-expressing, lung cancer cells significantly inhibited tumor cell growth and induced apoptosis. Finally, we found that SRC-3 expression is inversely correlated with gefitinib sensitivity and that SRC-3 knockdown results in epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancers becoming more sensitive to gefitinib. Taken together, these data suggest that SRC-3 may be an important oncogene and therapeutic target for lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=77955727897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955727897&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-0005

DO - 10.1158/0008-5472.CAN-10-0005

M3 - Article

VL - 70

SP - 6477

EP - 6485

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -